Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery
MitoCareX, a Nexentis subsidiary, is in early-stage evaluation of additional protein sourcing methods to expand in-vitro drug discovery flexibility.
Rhea-AI Summary
Nexentis (NXTS) reported that its wholly owned subsidiary, MitoCareX Bio, is evaluating additional established, commercially available approaches for obtaining proteins used in its in-vitro research activities.
The assessment aims to broaden available research tools, enhance access to protein materials and support flexibility as MitoCareX’s future drug discovery programs progress. The company described this process as part of a disciplined, methodical effort to develop reliable in-vitro research capabilities. The evaluation is at an early stage, and there is no assurance that any of the approaches under review will be adopted or provide anticipated benefits.
Positive
- None.
Negative
- None.
Details
Market Reaction – NXTS
On Sep 23, the day this news came out, the latest delayed price for NXTS is 3.55% below the previous close. Argus tracked a peak move of +4.9% during the session. Our momentum scanner has recorded 8 alerts for this stock so far that day. The latest delayed price is $1.36. Relative volume is exceptionally heavy at 7.5x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Terms
in-vitro technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Evaluation of additional commercially available approaches for obtaining proteins is intended to enhance access to research materials, increase research flexibility and support the advancement of MitoCareX’s future in-vitro drug discovery programs
Ness Ziona, Israel, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. , (NASDAQ: NXTS) (“Nexentis” or the “Company”), today announced that its wholly-owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”), a drug discovery company, is evaluating additional approaches for obtaining proteins used in its in-vitro research activities.
MitoCareX is evaluating established, commercially available approaches for obtaining proteins as part of its disciplined effort to broaden the research tools available for its in-vitro activities. The assessment will examine whether these approaches are suitable for MitoCareX’s research requirements and may support greater flexibility as its discovery programs progress.
By assessing additional established approaches for obtaining proteins for controlled in-vitro studies, MitoCareX seeks to broaden its research capabilities while also maintaining flexibility in the advancement of its discovery programs. The evaluation remains at an early stage, and there can be no assurance that any approach under consideration will be adopted or provide the anticipated benefits.
“Evaluating appropriate approaches to obtain proteins is part of our methodical approach to developing reliable in-vitro research capabilities,” said Dr. Alon Silberman, Chief Executive Officer of MitoCareX Bio. “Our goal is to assess tools and methods that may support the quality and consistency of our research while maintaining the flexibility required as our discovery programs progress.”
About MitoCareX Bio Ltd.
MitoCareX Bio Ltd., a wholly owned subsidiary of Nexentis Technologies Inc., is advancing a focused drug-discovery platform designed to translate multidisciplinary scientific capabilities into potential therapeutic candidates. By integrating biology, chemistry and computationally enabled research, MitoCareX supports ongoing research activities directed toward candidate identification and development within its drug-discovery efforts. https://mitocarexbio.com/
About Nexentis Technologies Inc.
Nexentis Technologies Inc. (NASDAQ: NXTS) owns
For additional details, please visit https://nexentistech.com/
Forward-looking Statements:
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses MitoCareX's evaluation of additional approaches for obtaining proteins, whether any such approaches are suitable for its research requirements, whether any approach under consideration will be adopted, and the potential of such approaches to enhance access to research materials, increase research flexibility, and support the advancement of MitoCareX's future in-vitro drug discovery programs. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause the Company’s and its subsidiaries’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of Nasdaq Capital Market; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 31, 2026 and other public reports filed with the SEC. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. We are not responsible for the contents of third-party websites.
Investor Relations Contact:
Michal Efraty
michal@efraty.com
